A one-time gene therapy treatment has shown remarkable success in slowing the progression of Huntington’s disease in a preliminary trial.
The experimental treatment, called AMT-130, reduced disease progression by 75% over three years in patients who received a high dose, compared to those on standard care, according to researchers.
While these early results are promising, they are preliminary and the treatment could still years away from potential FDA approval, with the earliest application expected in 2026.
Author: ABC News
Go to Source
News post in September 25, 2025, 3:04 am.
Visit Our Sponsor’s:
News Post In – News
